8 Einträge von 8 mit kidney patients
www.sipbb.ch
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 11 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG SAVE THE DATE – STARTUP WEEKEND BIEL/BIENNE 29-31 October 2021 27.01.2019 Contact us
Kombination Keywords swiss with | biel/bienne success | park news | menu sipbb | center manufacturing | event switzerland-innovation.com | share medtech | test patients | startup technology | more calciscon |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 268048
Subdomain:
extern (outbound) Link/Domain 11 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG SAVE THE DATE – STARTUP WEEKEND BIEL/BIENNE 29-31 October 2021 27.01.2019 Contact us
Kombination Keywords swiss with | biel/bienne success | park news | menu sipbb | center manufacturing | event switzerland-innovation.com | share medtech | test patients | startup technology | more calciscon |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 268048
www.sipbb.ch
Datum der Indexierung 28.02.2021 20:39:08
Subdomain:
extern (outbound) Link/Domain 11 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG Every crisis is also a chance 27.01.2019 Contact us
Kombination Keywords swiss startup | center stories | menu factory | park patients | biel/bienne innovation | test manufacturing | smart event | share switzerland-innovation.com | calciscon more | medtech technology |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 268048
Subdomain:
extern (outbound) Link/Domain 11 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG Every crisis is also a chance 27.01.2019 Contact us
Kombination Keywords swiss startup | center stories | menu factory | park patients | biel/bienne innovation | test manufacturing | smart event | share switzerland-innovation.com | calciscon more | medtech technology |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 268048
www.sipbb.ch
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 10 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG Startup-Weekend Biel/Bienne 2021 27.01.2019 Contact us
Kombination Keywords biel/bienne success | park with | swiss stories | menu calciscon | center manufacturing | innovation switzerland-innovation.com | share technology | switzerland event | test patients | startup more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 1052257
Subdomain:
extern (outbound) Link/Domain 10 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG Startup-Weekend Biel/Bienne 2021 27.01.2019 Contact us
Kombination Keywords biel/bienne success | park with | swiss stories | menu calciscon | center manufacturing | innovation switzerland-innovation.com | share technology | switzerland event | test patients | startup more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 1052257
www.sipbb.ch
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 10 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG 5. Digitaltag Schweiz 27.01.2019 Contact us
Kombination Keywords park stories | biel/bienne news | swiss with | innovation newsletter | switzerland event | menu manufacturing | center technology | test patients | share switzerland-innovation.com | more calciscon |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 1052257
Subdomain:
extern (outbound) Link/Domain 10 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG 5. Digitaltag Schweiz 27.01.2019 Contact us
Kombination Keywords park stories | biel/bienne news | swiss with | innovation newsletter | switzerland event | menu manufacturing | center technology | test patients | share switzerland-innovation.com | more calciscon |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 1052257
www.sipbb.ch
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 10 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG Exchange trainee at the Switzerland Innovation Park Biel/Bienne 27.01.2019 Contact us
Kombination Keywords swiss startup | park manufacturing | biel/bienne sipbb | menu technology | center switzerland-innovation.com | innovation patients | switzerland factory | test event | share smart | calciscon more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 1052257
Subdomain:
extern (outbound) Link/Domain 10 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG Exchange trainee at the Switzerland Innovation Park Biel/Bienne 27.01.2019 Contact us
Kombination Keywords swiss startup | park manufacturing | biel/bienne sipbb | menu technology | center switzerland-innovation.com | innovation patients | switzerland factory | test event | share smart | calciscon more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients with an elevated risk of calcification, and for the direction and monitoring of their treatment. It furthermore develops treatment concepts to improve the T50-Test with available drugs. Thereby Calciscon aims to establis
Text Inhalt Text aus URL
Log Metriken 1052257
www.sipbb.ch
Datum der Indexierung 29.03.2021 16:52:17
erkannte Namen Eberhard Unternehmungen |
Subdomain:
extern (outbound) Link/Domain 0 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description pdf
Kombination Keywords innovation which | park sciences | research partners | biel/bienne center | switzerland medtech | projects technology | companies university | with bern | swiss their | gmbh applied |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients is central to medical products. Strict directives harmonized throughout Europe require continuous quality control and market surveillance. A certified quality management system is thus essential and is usually a pre-requi
Text Inhalt Text aus URL
Log Metriken 460034
erkannte Namen Eberhard Unternehmungen |
Subdomain:
extern (outbound) Link/Domain 0 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description pdf
Kombination Keywords innovation which | park sciences | research partners | biel/bienne center | switzerland medtech | projects technology | companies university | with bern | swiss their | gmbh applied |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients is central to medical products. Strict directives harmonized throughout Europe require continuous quality control and market surveillance. A certified quality management system is thus essential and is usually a pre-requi
Text Inhalt Text aus URL
Log Metriken 460034
www.sipbb.ch
Datum der Indexierung 13.03.2021 18:43:46
erkannte Namen Eberhard Unternehmungen |
Subdomain:
extern (outbound) Link/Domain 0 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description pdf
Kombination Keywords innovation which | switzerland partners | research sciences | park medtech | biel/bienne technology | projects university | companies center | with bern | swiss their | gmbh applied |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients is central to medical products. Strict directives harmonized throughout Europe require continuous quality control and market surveillance. A certified quality management system is thus essential and is usually a pre-requi
Text Inhalt Text aus URL
Log Metriken 460034
erkannte Namen Eberhard Unternehmungen |
Subdomain:
extern (outbound) Link/Domain 0 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description pdf
Kombination Keywords innovation which | switzerland partners | research sciences | park medtech | biel/bienne technology | projects university | companies center | with bern | swiss their | gmbh applied |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients. The first patient group to benefit from the T50-Test are kidney patients (i.e. chronic kidney disease, dialysis and renal transplant patients). The extension to further patient groups at elevated cardiovascular calcification risk and patients is central to medical products. Strict directives harmonized throughout Europe require continuous quality control and market surveillance. A certified quality management system is thus essential and is usually a pre-requi
Text Inhalt Text aus URL
Log Metriken 460034
www.sipbb.ch
Datum der Indexierung 17.02.2021 10:25:09
Subdomain:
extern (outbound) Link/Domain 1 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG GET YOUR PERSONALIZED NEWSLETTER More Success Stories Contact us
Kombination Keywords test more | patients share | dimofac treatment | digital risk | calcification patient | regions project | kidney elevated | espi machine | from with | first measuring |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients The first patient group to benefit from the T50 Test are kidney patients i e chronic kidney disease dialysis and renal transplant patients The extension to further patient groups at elevated cardiovascular calcification risk and the d patients with an elevated risk of calcification and for the direction and monitoring of their treatment It furthermore develops treatment concepts to improve the T50 Test with available drugs Thereby Calciscon aims to establish t
Text Inhalt Text aus URL
Log Metriken 268048
Subdomain:
extern (outbound) Link/Domain 1 in www.sipbb.ch
intern (inbound) Link/Domain www.sipbb.ch
Alle Links in alle Links in www.sipbb.ch
HTML Description Calciscon AG GET YOUR PERSONALIZED NEWSLETTER More Success Stories Contact us
Kombination Keywords test more | patients share | dimofac treatment | digital risk | calcification patient | regions project | kidney elevated | espi machine | from with | first measuring |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
kidney patients The first patient group to benefit from the T50 Test are kidney patients i e chronic kidney disease dialysis and renal transplant patients The extension to further patient groups at elevated cardiovascular calcification risk and the d patients with an elevated risk of calcification and for the direction and monitoring of their treatment It furthermore develops treatment concepts to improve the T50 Test with available drugs Thereby Calciscon aims to establish t
Text Inhalt Text aus URL
Log Metriken 268048